IP Library Granted Patent US 9,993,559
Granted Patent B2
US 9,993,559 · App. 15/166,409 · Granted Jun 12, 2018

N-alkyl lactam ethers, and compositions and uses thereof

Inventors: Osama M. Musa (Kinnelon, NJ); Kolazi S. Narayanan (Wayne, NJ)
Assignee: ISP INVESTMENTS LLC
A61K47/22A01N25/02A01N43/653A01N43/78A01N53/00A61K8/4913A61K8/58A61K9/0014A61K9/7084A61K31/405A61K31/4174A61K31/65A61K31/7048A61K47/18A61Q5/02A61Q19/00B01D53/1468B01D53/1487B01D53/1493B01F17/0042C07D207/27C07D211/76C07D223/10C07D401/12C07D403/12C08F2/06C08K5/3415C08L71/02C09D7/001C09D7/1233C09D9/005C09D11/033C09D11/36C09D17/002C09K3/00C09K3/18C09K8/524C09K15/30C10M133/44C11D3/32C11D3/43C11D7/263C11D7/3281G01N21/88H01M10/056A61Q17/005C08L2201/56C09K2208/22C10M2215/224
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,993,559
App. No.
15/166,409
Granted
Jun 12, 2018
Kind
B2
Abstract

Described is a class of symmetrical and asymmetrical N-alkyl lactam ethers. One preferred ether is bis-N-ethyl pyrrolidone ether. Preferred compositions and uses of the ethers are in performance chemicals, personal care, and pharmaceutical fields, where they function a variety of roles, including as a solvent, solubilizer, freezing point depressor, diluent, extracting agent, cleaning agent, degreaser, absorbent and/or dispersion agent.

Claims (7)

1. A compound represented by the structure:

wherein:

one of A l and A 2 is —CH 2 CH 2 — and the other is —CH 2 CH 2 CH 2 —;

said Q 1 and Q 2 are independently selected from a linear or branched C 1-6 alkyl; and

each said R is independently selected from the group consisting of hydrogen, and C 1-4 alkyl.

2. The compound according to claim 1 selected from the group consisting of:

3. A sun care composition comprising the compound of claim 1 and one or more UV absorbers selected from the group consisting of: p-aminobenzoic acid (PABA), Padimate O, ensulizole, cinoxate, benzophenone-3, enzophenone-8, homosalate, meradimate, octocrylene, 2-ethylhexyl-p-methoxycinnamate, octyl salicylate, sulisobenzone, trolamine salicylate, avobenzone, ecamsule, titanium dioxide, zinc oxide, 4-methylbenzylidene, Tinosorb M, neo heliopan AP, mexoryl XL, benzophenone-9, Uvinul T150, Uvinul A Plus, Uvasorb HEB, Parsol SLX, isopentenyl-4-methoxycinnamate, and combinations thereof.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jan 10, 2020
From: THE BANK OF NOVA SCOTIA
To: AVOCA LLC; HERCULES LLC; ISP INVESTMENTS LLC; PHARMACHEM LABORATORIES LLC
Reel/Frame 051557/0504 →
SECURITY AGREEMENT Recorded Jul 3, 2017
From: AVOCA, INC.; HERCULES LLC; ISP INVESTMENTS LLC; PHARMACHEM LABORATORIES, INC.
To: THE BANK OF NOVA SCOTIA, AS ADMINISTRATIVE AGENT
Reel/Frame 043084/0753 →
CHANGE OF NAME Recorded May 24, 2017
From: ISP INVESTMENTS INC.
To: ISP INVESTMENTS LLC
Reel/Frame 042560/0842 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2016
From: MUSA, OSAMA M.; NARAYANAN, KOLAZI S.
To: ISP INVESTMENTS INC.
Reel/Frame 038907/0070 →
Continuity (4)
Continuation 14057075 · Oct 18, 2013
Continuation 13296361 · Nov 15, 2011
Provisional Application 61414703 · Nov 17, 2010
Related Publication 20160271254A1 · Sep 22, 2016